2'-Fucosyllactose 41263-94-9

99% up by HPLC

Inquire now

Product categories

New Products

Product Details

Product Information

Product name	2'-Fucosyllactose
CAS No.	41263-94-9
Molecular Formula	C18H32O15
Molecular Weight	488.443
Molecular Structure
Quality Standard	99% up by HPLC
Appearance	White to off-white powder

COA

Items	Standard	Results
Appearance	White to ivory-coloured spray-dried powder	Complies
Solubilityl in water	min.500g/L(ambient temperature)	Complies
Appearance in solution	colourless to slightly yellow	Complies
GMO detection	negative	negative
2'-Fucosyllactose	≥90%(%DM)	90.8%
Lactose	≤5% (Area)	0.8%
Fucose	≤3% (Area)	0.6%
3-Fucosyllactose	≤5% (Area)	1.8%
Difucosyllactose	≤5% (Area)	2.0%
Fucosyl-Galactose	≤3% (Area)	1.0%
Water Content	≤9.0%	6.2%
Protein content	≤100μg/g	0.2μg/g
Total Ash	≤0.5%	0.12%
Conclusion	Qualified

Usage

2'-Fucosyllactose (2'-FL) is a type of human milk oligosaccharide (HMO) that is naturally found in breast milk. It is a complex carbohydrate that cannot be digested by infants, but it plays an important role in promoting the growth and development of beneficial gut bacteria, as well as supporting the immune system.

The benefits of 2'-FL include:

1. Prebiotic effects: 2'-FL promotes the growth of beneficial gut bacteria, such as Bifidobacterium and Lactobacillus, while inhibiting the growth of harmful bacteria. This helps to support a healthy digestive system and immune function.

2. Anti-inflammatory effects: 2'-FL has been shown to have anti-inflammatory properties, which may help to reduce inflammation and support overall health.

3. Immune system support: 2'-FL supports the development and function of the immune system, including the production of antibodies and the activation of immune cells.

4. Cognitive development: Studies have shown that infants who consume breast milk containing 2'-FL have better cognitive development and may have a lower risk of developmental delays.

5. Reduced risk of infections: Infants who consume breast milk containing 2'-FL have a lower risk of infections, including respiratory infections and diarrhea.

Overall, 2'-FL is a beneficial component of breast milk that supports the growth and development of infants and provides important health benefits. It is now being added to infant formula and other products as a way to provide similar benefits to infants who are not able to consume breast milk.

Hot Tags : 41263-94-9 2'-Fucosyllactose Fucosyllactose Human Milk Oligosaccharides 2\'-FL HMO

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Subject : 2'-Fucosyllactose 41263-94-9

Related Products

Uridine 5'-monophosphate disodium salt UMP-Na2 3387-36-8

99% up by HPLC

Nilotinib 641571-10-0

99% up by HPLC

Latanoprost 130209-82-4

99% up

Bilberry Extract 84082-34-8

5:1 10:1 25% anthocyanidins

Sodium D-Pantothenate 867-81-2

In-house specification: Assay 9.30%-9.70% of Na, 5.60%-6.00% of N

Entecavir Intermediate 142217-81-0

98% up by HPLC, S.Impurity < 0.1%, T.Impurities <0.3%

Liraglutide 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.